The Vdr: Why Your Vitamin D3 Might Not Be Protecting Your Ageing Brain
Quick Read Vitamin D does more than support bones. It acts as a signalling molecule that switches genes on and
We write a new article on supplements every day , all detailed, with citations.
Once a week we send an email containing a list of the last 7 days articles. Please sign up and also feel free to share the articles with friends and family who you think might benefit.
Simon Parrott – Vitacuity Ltd
Memory lapses in midlife may signal degradation of myelin, the fatty insulation around brain nerve fibres that carries electrical signals. DHA, an omega-3 fat found in fish and algae, is a critical structural component of myelin and your brain cannot produce it on its own. As you age, myelin thins and DHA transport into the brain becomes less efficient, even if you eat adequate fish.
Research shows people with higher blood omega-3 levels have less brain damage visible on scans, better memory preservation over 17 years, and lower dementia risk. A clinical trial found that 2 grams of DHA daily slowed hippocampal shrinkage and improved cognitive function in people with early memory problems. High-dose omega-3 supplements appeared to slow cognitive ageing by 2.5 years in people with heart disease. However, results across trials are mixed, and most tested doses are higher than standard fish oil supplements provide.
About one quarter of people carry a gene variant called APOE4 that disrupts how their brain uses DHA, meaning they may need higher doses earlier in life for protection. The form of DHA matters too, with emerging evidence suggesting that some supplement types may deliver brain DHA more effectively than others.
Verdict: DHA supplementation at 1 to 2 grams daily appears to preserve brain structure and may slow cognitive decline, particularly if started in midlife before memory problems emerge, though larger trials are still needed to confirm optimal doses and long-term benefits.
What if the memory lapses you’ve been quietly brushing off, forgetting a word mid-sentence, losing your train of thought, walking into a room and drawing a blank, aren’t just “getting older”? What if they’re a sign of something structural happening inside your brain right now, something that begins decades before any diagnosis, and something that a specific nutrient might actually slow down? Most people assume cognitive decline is inevitable, a slow dimming of the lights that nobody can stop. But a growing body of research is pointing to a far more specific culprit: the gradual breakdown of the fatty sheaths that wrap around your brain’s nerve fibres, and a surprising connection to how much DHA you have circulating in your blood.
To understand why DHA matters so much in midlife, you need a quick picture of what’s actually happening inside your skull.
Your brain communicates through neurons, long, wire-like cells called axons that carry electrical signals. For those signals to travel quickly and efficiently, axons need to be wrapped in a protective, insulating layer called myelin. Think of myelin like the plastic coating around an electrical cable. Without it, signals slow down, short-circuit, or simply fail to arrive at all.
Myelin is made almost entirely of fat, and not just any fat. Around 60% of the dry weight of the human brain is fat, and one of its most critical structural components is docosahexaenoic acid (DHA), a long-chain omega-3 fatty acid found in oily fish, algae, and marine life. DHA is embedded in the phospholipid membranes of neurons, maintaining their fluidity, flexibility and ability to transmit signals [13].
Here’s the problem: your brain cannot make meaningful amounts of DHA on its own. It depends almost entirely on what you eat, and then on a remarkably complex delivery system to get DHA across the blood-brain barrier (BBB), the tightly controlled gateway between your bloodstream and your brain [7].
As we age, several things go wrong simultaneously. Myelin begins to thin and degrade. Small blood vessels in the brain become damaged, a process called small-vessel ischemic disease, and this shows up on brain scans as white matter lesions (WMLs): areas of damaged, poorly myelinated tissue scattered through the brain’s white matter [3]. And the efficiency of DHA transport into the brain appears to decline, meaning even people eating adequate amounts of oily fish may not be getting enough DHA where it’s actually needed [4].
The result, over years and decades, is a brain that is literally losing its insulation, and with it, its speed, its sharpness, and its resilience.
This is perhaps the most structurally concrete finding in the entire body of DHA and brain research. It’s not just about test scores or fuzzy measures of “cognition”, it’s visible on brain scans.
A 2024 randomised clinical trial published in *JAMA* examined whether omega-3 supplementation could prevent the progression of white matter lesions, those patches of demyelinated, damaged tissue that accumulate with age [3][15]. The trial found that older adults with lower intake and lower tissue levels of EPA and DHA had significantly more white matter lesions than those with higher omega-3 status. The researchers framed this not as a coincidence but as a potentially modifiable risk factor, specifically linking small-vessel ischemic disease (a primary driver of white matter damage) to omega-3 insufficiency.
This is important because white matter lesions are not benign. They are associated with slower processing speed, memory problems, and meaningfully increased dementia risk. Seeing them on a brain scan is not just an academic observation, it reflects real structural deterioration happening in the brain’s communication network.
Evidence grade: Promising, This is a randomised clinical trial in older adults, which is a significant step up from observational data. However, the long-term prevention question requires larger, longer studies to confirm.
One of the most compelling long-term datasets on DHA and brain health comes from the Three-City Study, a large French prospective cohort that followed 1,279 non-demented older adults for up to 17 years [10].
Researchers measured plasma EPA+DHA levels at baseline and then tracked dementia incidence, cognitive decline, and, in a subset of 467 participants, changes in brain volume on MRI over 10 years.
The findings were striking. Higher plasma EPA+DHA levels were consistently associated with: – A 13% lower risk of dementia per standard deviation increase in omega-3 levels (hazard ratio 0.87, 95% CI 0.76–0.98) – Significantly less decline in global cognition (p = .04) – Less decline in memory (p = .06) – Less atrophy of the medial temporal lobe, the brain region most critical for memory formation, (p = .02)
This is a prospective study, not an intervention trial, so it shows association rather than confirmed cause and effect. But 17 years of follow-up in over a thousand people is a substantial dataset, and the relationship between omega-3 status and brain preservation held up even after adjusting for other variables.
A smaller, supporting study from 2012 also found that plasma DHA and EPA levels predicted the rate of medial temporal lobe atrophy in older adults over time, independently of other risk factors [6].
Evidence grade: Promising to strong, The prospective data is consistent and long-term, but randomised trial data confirming causation is still limited.
If the observational data raises the question, this trial begins to answer it.
A 2017 randomised, double-blind, placebo-controlled trial recruited 240 adults aged 65 and over with mild cognitive impairment (MCI) and randomly assigned them to either 2g/day of DHA or placebo (corn oil) for 12 months [14].
The results, measured at 6 and 12 months, were notable:
– Cognitive function improved significantly in the DHA group across multiple domains, including Full-Scale IQ (p = 0.039), Information processing (p < 0.001), and Digit Span, a measure of working memory (p < 0.001) - Hippocampal volume, one of the most sensitive structural markers of Alzheimer’s progression, was significantly better preserved in the DHA group, with less shrinkage in the left hippocampus (p = 0.016), right hippocampus (p = 0.008), total hippocampus (p = 0.023), and overall cerebrum (p = 0.032)
219 of the 240 participants completed the trial. Serum DHA levels rose by 3.85% in the intervention group versus 1.06% in placebo, confirming that supplementation was actually increasing DHA status.
This is one of the cleaner structural demonstrations we have: DHA supplementation, at a clinically meaningful dose, appears to slow the physical shrinkage of the brain region most critical for memory, in people who already have early cognitive impairment.
Evidence grade: Promising, One well-designed RCT of moderate size (n=219 completers) and 12-month duration. Larger confirmatory trials are needed, and the population was specifically people with MCI, not healthy adults.
One of the most cited recent findings in this area involves people with coronary artery disease (CAD), a population at elevated cognitive risk, who were given 3.36g/day of combined EPA and DHA.
According to a 2023 review in *Current Opinion in Lipidology*, this high-dose supplementation was associated with slowing cognitive ageing by an estimated 2.5 years compared to placebo, in cognitively healthy individuals with clinical CAD [2][11].
This dose, over 3 grams per day of combined EPA and DHA, is substantially higher than the average Western dietary intake (estimated at under 200mg/day in many populations) and higher than the 1g often found in standard fish oil capsules. The finding raises the dose question front and centre: most trials that have failed to show cognitive benefit may simply have used doses too low to meaningfully shift brain DHA status.
Of 15 randomised controlled trials in cognitively healthy people over 55, the same review noted that seven showed benefit and eight did not, and points explicitly to dose, trial duration, and individual genetic factors as the likely drivers of this inconsistency [2][11].
Evidence grade: Promising, The 2.5-year slowing effect comes from one population (CAD patients) and the broader RCT picture is mixed. But the dose signal is consistent and important.
Not all brains respond to DHA the same way, and the reason is increasingly well understood.
Around 25% of people carry at least one copy of the APOE4 allele, the most significant known genetic risk factor for Alzheimer’s disease. What’s now emerging is that APOE4 doesn’t just increase risk in a vague, general way, it specifically disrupts DHA metabolism and transport in the brain [1][4][8].
Reviews published in 2024 in *Progress in Lipid Research* and elsewhere outline multiple mechanisms by which APOE4 undermines DHA supply to the brain:
1. Accelerated DHA catabolism, APOE4 carriers appear to break down DHA faster than non-carriers 2. Impaired transport across the blood-brain barrier, the machinery that carries DHA from blood into brain tissue appears less efficient in APOE4 carriers 3. Compromised lipidation, APOE4 interferes with the packaging and circulation of DHA-carrying lipoproteins
The clinical implication is significant: APOE4 carriers may be chronically under-supplied with brain DHA even on a seemingly adequate diet, and may therefore need higher doses to compensate.
Crucially, the research suggests timing matters enormously. Early DHA supplementation in cognitively normal APOE4 carriers appears beneficial. Once Alzheimer’s disease has developed, the picture reverses, at that stage, non-carriers may actually benefit more from DHA, while the overall effectiveness of supplementation is limited [1][4]. This points to DHA as a preventive strategy, not a treatment.
Evidence grade: Promising, The mechanisms are well-characterised and biologically plausible. Clinical trial data in APOE4 carriers is still limited in size and duration, but the direction of evidence is consistent.
One of the most underappreciated findings in recent DHA research concerns not just *how much* DHA you take, but *what form* it takes, because the brain has a highly specific delivery system.
Research highlighted in a 2020 perspective in *Advances in Nutrition* reveals that DHA is primarily transported across the blood-brain barrier not as a free fatty acid or standard triglyceride, but in a specific form called lysophosphatidylcholine (LPC), carried by a dedicated transporter protein called MFSD2A [7].
This is a critical detail that explains one of the most persistent puzzles in the DHA research: why many supplementation trials using standard fish oil (DHA in triglyceride form) have failed to show cognitive benefit, even at seemingly reasonable doses. If the preferred form for brain uptake is LPC-DHA, then conventional fish oil may simply not be delivering DHA to the brain as efficiently as assumed.
A separate 2026 mouse study (currently the most recent in the database) found that the position of DHA within the triglyceride molecule also affects how well it accumulates in the brain, with DHA esterified at the sn-2 position producing nearly double the brain DHA concentration compared to controls, and significantly improving hippocampal structure and memory performance [5]. While this is mouse data and cannot be directly applied to humans, it points to a biologically meaningful distinction that human trials will eventually need to address.
Evidence grade: Early stage, The LPC pathway is well-established mechanistically, and the sn-2 position data is promising but currently animal only. This area of research has significant implications for how we think about supplement formulation.
The research here is genuinely exciting, but intellectual honesty demands we name the gaps clearly.
The RCT picture is mixed and inconsistent. Of 15 randomised trials in cognitively healthy adults over 55, seven showed benefit and eight didn’t [2][11]. This isn’t a reason to dismiss DHA, but it does mean we cannot yet say with confidence that supplementing healthy adults will definitively slow cognitive decline. Dose, duration, form, genetic background, sex, and baseline cognitive status all appear to matter, and most trials haven’t controlled for all of these simultaneously.
We don’t have long enough trials. Cognitive decline unfolds over decades. Most RCTs run for 12–24 months. Even a well-designed two-year trial may simply be too short to detect a meaningful structural effect on a process that takes 20 years to manifest clinically.
The form and delivery question is unresolved. If LPC-DHA is the primary carrier across the blood-brain barrier, but most supplements deliver DHA as triglycerides, we may be measuring the wrong thing in many trials. The sn-2 position research is currently animal-only [5]. We need human trials comparing different DHA forms and measuring actual brain DHA uptake.
The APOE4 picture needs dedicated trials. The evidence that APOE4 carriers have disrupted DHA metabolism is mechanistically solid [1][4][8], but we don’t yet have large, long-term RCTs specifically in APOE4 carriers testing whether high-dose DHA meaningfully reduces their conversion to MCI or dementia. This is arguably the most important trial that needs to happen.
The white matter findings need more intervention data. The 2024 omega-3 and white matter lesion trial [3][15] is genuinely important, but we need more RCT data specifically measuring myelin preservation and white matter lesion progression as primary endpoints, with clear dose-response data.
We also don’t know the optimal dose for brain protection. The most compelling cognitive findings involve 2–3.36g/day of DHA or combined EPA+DHA. Most people consuming standard fish oil capsules are getting 300–500mg. Whether lower doses provide any structural brain benefit is uncertain.
Let’s reason through this like a sensible, informed person rather than a cautious liability-conscious academic.
Here’s what the evidence actually shows: DHA is the dominant structural fat in your brain. It maintains myelin integrity, supports synaptic function, reduces neuroinflammation, and its blood levels track reliably with brain volume, white matter health, and dementia risk over long time horizons. People with higher omega-3 status have measurably better brain preservation, less shrinkage of memory-critical structures, and lower dementia incidence over 17 years [10]. A 12-month RCT in people with early cognitive impairment found that 2g/day slowed hippocampal atrophy and improved cognitive function [14]. High-dose supplementation (3.36g/day) appears to slow cognitive ageing in high-risk adults by 2.5 years [2].
Meanwhile, DHA supplementation at normal doses is extremely safe. It is a dietary fatty acid. It is not toxic at 1–3g/day. The risk of not having enough brain DHA, evidenced by the consistent structural and cognitive associations above, is far more real than any risk of supplementing.
So what should you actually do?
1. Take DHA seriously, and take enough of it. Standard fish oil capsules providing 300mg of DHA are probably not sufficient to meaningfully shift brain DHA status, based on the doses where benefits were observed in trials. Aim for at least 1–2g of DHA daily, which typically means choosing a concentrated omega-3 supplement, not a standard one-capsule-a-day fish oil. If you have early memory concerns, a family history of dementia, or carry the APOE4 gene, the case for reaching 2g/day is stronger still.
2. Don’t wait. The APOE4 research is particularly clear on this: the window for DHA to make a difference appears to be *before* cognitive decline sets in, not after [1][4]. Midlife, your 40s and 50s, is exactly when building and maintaining brain DHA reserves matters most.
3. Consider the form. The emerging evidence on LPC-DHA and sn-2 positioned DHA [5][7] suggests that not all omega-3 supplements are equally effective at reaching the brain. Look for supplements where DHA is in phospholipid form (krill oil is one such source), or at minimum, choose a high-quality, concentrated fish oil. This is an evolving area, watch it.
4. Eat oily fish too. Supplementation and diet work together. Salmon, sardines, mackerel, and anchovies provide DHA in food matrix alongside other nutrients. Two to three portions a week provides a meaningful dietary baseline.
5. If you know your APOE4 status, start earlier and go higher. If you’ve had genetic testing and carry APOE4, the evidence suggests your brain may metabolise DHA less efficiently [1][4][8]. A higher supplemental dose, discussed with a healthcare provider, is a rational response to a biological reality.
DHA is not a miracle. It will not reverse damage that’s already done. But the structural case for maintaining high brain DHA levels through midlife and beyond, to preserve myelin, protect white matter, and slow the physical shrinkage of memory-critical brain tissue, is the most mechanistically coherent and empirically grounded story in cognitive nutrition right now.
And that’s worth paying attention to.
*Vitacuity has analysed over 1.77 million research papers to bring you the most relevant, evidence-graded insights on brain health and healthy ageing. The 15 papers cited in this article were selected from our database as the strongest and most relevant available evidence on DHA, axon health, and cognitive decline.*
[1] Effects of DHA on cognitive dysfunction in aging and Alzheimer’s disease: The mediating roles of ApoE (2024). *Progress in Lipid Research*. DOI: 10.1016/j.plipres.2023.101256 | https://pubmed.ncbi.nlm.nih.gov/37890592/
[2] Omega-3 fatty acids and cognitive function (2023). *Current Opinion in Lipidology*. DOI: 10.1097/MOL.0000000000000862 | https://pubmed.ncbi.nlm.nih.gov/36637075/ | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11878108/
[3] ω-3 PUFA for Secondary Prevention of White Matter Lesions and Neuronal Integrity Breakdown in Older Adults: A Randomized Clinical Trial (2024). https://pubmed.ncbi.nlm.nih.gov/39088212/
[4] Effects of APOE4 on omega-3 brain metabolism across the lifespan (2024). https://pubmed.ncbi.nlm.nih.gov/38609814/
[5] High sn-2 DHA in Dietary Triglyceride Enhances Cognitive Performance of Mice (2026). *Journal of Food Science*. DOI: 10.1111/1750-3841.70646 | https://pubmed.ncbi.nlm.nih.gov/41454601/
[6] Plasma long-chain omega-3 fatty acids and atrophy of the medial temporal lobe (2012). https://pubmed.ncbi.nlm.nih.gov/22855869/
[7] Perspective: The Potential Role of Circulating Lysophosphatidylcholine in Neuroprotection against Alzheimer Disease (2020). *Advances in Nutrition*. DOI: 10.1093/advances/nmaa024 | https://pubmed.ncbi.nlm.nih.gov/32190891/ | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7360459/
[8] Effects of DHA on cognitive dysfunction in aging and Alzheimer’s disease: The mediating roles of ApoE (2024). *Progress in Lipid Research*. DOI: 10.1016/j.plipres.2023.101256 | https://pubmed.ncbi.nlm.nih.gov/37890592/
[9] Omega-3 DHA and EPA for cognition, behavior, and mood: clinical findings and structural-functional synergies with cell membrane phospholipids (2007). https://pubmed.ncbi.nlm.nih.gov/18072818/
[10] Blood polyunsaturated omega-3 fatty acids, brain atrophy, cognitive decline, and dementia risk (2020). *Alzheimer’s & Dementia*. DOI: 10.1002/alz.12195 | https://pubmed.ncbi.nlm.nih.gov/33090665/
[11] Omega-3 fatty acids and cognitive function (2023). *Current Opinion in Lipidology*. DOI: 10.1097/MOL.0000000000000862 | https://pubmed.ncbi.nlm.nih.gov/36637075/ | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11878108/
[12] Structured Long-Chain Omega-3 Fatty Acids for Improvement of Cognitive Function during Aging (2022). *International Journal of Molecular Sciences*. DOI: 10.3390/ijms23073472 | https://pubmed.ncbi.nlm.nih.gov/35408832/ | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8998232/
[13] Docosahexaenoic acid, 22:6n-3: Its roles in the structure and function of the brain (2019). *International Journal of Developmental Neuroscience*. DOI: 10.1016/j.ijdevneu.2019.10.004 | https://pubmed.ncbi.nlm.nih.gov/31629800/
[14] Effects of DHA Supplementation on Hippocampal Volume and Cognitive Function in Older Adults with Mild Cognitive Impairment: A 12-Month Randomized, Double-Blind, Placebo-Controlled Trial (2017). *Journal of Alzheimer’s Disease*. DOI: 10.3233/JAD-160439 | https://pubmed.ncbi.nlm.nih.gov/27716665/
[15] ω-3 PUFA for Secondary Prevention of White Matter Lesions and Neuronal Integrity Breakdown in Older Adults: A Randomized Clinical Trial (2024). https://pubmed.ncbi.nlm.nih.gov/39088212/
This article is for informational purposes only and does not constitute medical advice. Food supplements should not be used as a substitute for a varied and balanced diet and healthy lifestyle. If you are pregnant, breastfeeding, taking medication or have a medical condition, consult your doctor before taking any supplement. These statements have not been evaluated by the Food and Drug Administration (FDA) or the Medicines and Healthcare products Regulatory Agency (MHRA). This product is not intended to diagnose, treat, cure, or prevent any disease.
Quick Read Vitamin D does more than support bones. It acts as a signalling molecule that switches genes on and
Quick Read Multiple large studies show that people who drink coffee regularly have lower rates of dementia and cognitive decline.
Free guide: The research behind brain health supplements
Plus our weekly research digest — straight to your inbox.
Just leave your email address.